U.S. Markets close in 2 hrs 56 mins
  • S&P 500

    4,459.87
    -20.83 (-0.46%)
     
  • Dow 30

    34,654.55
    -159.84 (-0.46%)
     
  • Nasdaq

    15,105.47
    -56.06 (-0.37%)
     
  • Russell 2000

    2,249.73
    -25.88 (-1.14%)
     
  • Crude Oil

    69.39
    +1.04 (+1.52%)
     
  • Gold

    1,790.70
    -7.80 (-0.43%)
     
  • Silver

    23.95
    -0.38 (-1.58%)
     
  • EUR/USD

    1.1823
    -0.0025 (-0.2128%)
     
  • 10-Yr Bond

    1.3290
    +0.0250 (+1.92%)
     
  • Vix

    17.96
    -0.18 (-0.99%)
     
  • GBP/USD

    1.3773
    -0.0013 (-0.0909%)
     
  • USD/JPY

    110.2260
    -0.0330 (-0.0299%)
     
  • BTC-USD

    47,977.57
    -92.72 (-0.19%)
     
  • CMC Crypto 200

    1,232.19
    -1.10 (-0.09%)
     
  • FTSE 100

    7,095.53
    -53.84 (-0.75%)
     
  • Nikkei 225

    30,181.21
    +265.07 (+0.89%)
     

Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Molecular Partners AG (NASDAQ: MOLN) reported on the clinical progress of its antiviral candidate, ensovibep, as part of a presentation with its partner Novartis AG (NYSE: NVS) at the Credit Suisse ESG Forum Switzerland virtual event.

  • Ensovibep is currently being studied in Phase 2 single-arm pilot study in ambulatory patients in the Netherlands; a global Phase 2/3 study in ambulatory patients, in collaboration with Novartis (EMPATHY); and a National Institutes of Health-sponsored global Phase 3 study in hospitalized patients as part of the ACTIV-3 master protocol.

  • Interim data from EMPATHY Phase 2/3 trial is expected in H2 2021, and complete topline data expected in early 2022.

  • ACTIV-3 study is enrolling, with topline data expected in 2022.

  • The management outlined the initiation of a subcutaneous program expected in 2H of 2021 to evaluate ensovibep delivered subcutaneously to healthy individuals and subsequently to COVID-19 patients.

  • The Company also shared preclinical data showing that ensovibep retains full potency and viral inhibition against all known COVID-19 variants in circulation, including the key Delta variants.

  • In March 2021, the Company announced positive initial data from its Phase 1 study of ensovibep in healthy volunteers, which showed that ensovibep was safe and well-tolerated with a half-life of 2-3 weeks.

  • Price Action: MOLN shares are up 1.75% at $19.19, and NVS shares are down 0.09% at $92.02 during the premarket session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.